Infectious bone defects refer to bone defects accompanied by infection or those that occur during the treatment of bone infection and require surgical intervention. Due to the prolonged course of the disease and the destruction of the osteogenic microenvironment, the treatment is extremely difficult, and two major problems need to be solved: infection control and bone defect repair. In recent years, breakthrough progress has been made in this field. In mechanism research, the pathways by which pathogenic bacteria activate inflammatory responses to disrupt bone repair and the drug-resistance mechanism of methicillin-resistant Staphylococcus aureus (MRSA) have been clarified, providing molecular targets for targeted intervention. In terms of technology, interdisciplinary breakthroughs, such as the combination of targeted release of antibacterial drugs with microcarrier-controlled release systems, low-temperature additive manufacturing, and percutaneous sealing technology for external fixators, have solved key clinical problems. In material development, functional materials like cobalt-titanium-based implants and composite systems integrating antibiotics with bone growth factors have achieved synergy between anti-infection and bone repair. Clinical translation has yielded systematic solutions, and multicenter trials have confirmed that their efficacy is superior to traditional methods, breaking the dilemma that anti-infection and bone repair cannot be achieved simultaneously. For bone defect repair, bone repair materials include autologous bone, allogeneic bone, heterologous bone, and artificial bone. Autologous bone is regarded as the gold standard, and technologies to enhance biological activity have emerged in recent years. The Masquelet technique (membrane-induced technique) involves a two-stage surgery; the induced membrane exerts multiple effects, and its large-scale application in our center has achieved favorable outcomes. The Ilizarov technique is based on the Law of Tension-Stress, which has both advantages and limitations, and has been modified in multiple dimensions to form a mature technical system. However, the treatment of infectious bone defects still faces challenges such as unclear mechanisms of persistent infection and intracellular colonization of bacteria. In the future, interdisciplinary collaboration is required to establish an infection control-microenvironment remodeling-structural reconstruction system, promoting the development of personalized, minimally invasive, and intelligent treatment. Additionally, synergistic breakthroughs in clinical technology and biomaterials are needed to overcome this intractable orthopedic disease.

The aim of this updated guideline is to provide comprehensive recommendations for the management of gout in patients with common comorbidities, such as chronic kidney disease(CKD), cardiovascular disease(CVD), diabetes, osteoarthritis(OA), and gastrointestinal disorders. This guideline was developed by a multidisciplinary expert panel consisting of specialists in endocrinology, rheumatology, nephrology, cardiology, gastroenterology, and methodology. The development process adhered to standard methodologies, including PICO(population, intervention, comparator, and outcomes) question deconstruction, systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation(GRADE) for evidence and recommendation evaluation, Delphi voting, and expert consensus. The guideline presents 26 evidence-based recommendations addressing 7 clinical questions for patients with hyperuricemia and gout in the context of comorbidities. Key recommendations include the maintenance of strict serum urate targets, particularly for patients with CKD stage≥3, chronic gouty arthritis, and OA, in order to prevent disease progression. In patients with CVD or diabetes, intra-articular triamcinolone is preferred over systemic glucocorticoids. Prioritized anti-inflammatory treatments for patients with CKD, gastrointestinal diseases and OA are recommended. The guideline also introduces emerging therapies, such as interleukin-1 inhibitors and selective urate transport inhibitors, as potential treatment options for refractory cases. The update offers a comprehensive, patient-centered approach to managing gout, particularly in individuals with associated comorbidities. Multidisciplinary collaboration and emerging new treatments and evidence ensure the optimization of the recommendations.

PURPOSE: We carried out the study aiming to explore and analyze the risk factors, the distribution of pathogenic bacteria, and their antibiotic-resistance characteristics influencing the occurrence of surgical site infection (SSI), to provide valuable assistance for reducing the incidence of SSI after traumatic fracture surgery. METHODS: A retrospective case-control study enrolling 3978 participants from January 2015 to December 2019 receiving surgical treatment for traumatic fractures was conducted at Tangdu Hospital of Air Force Medical University. Baseline data, demographic characteristics, lifestyles, variables related to surgical treatment, and pathogen culture were harvested and analyzed. Univariate analyses and multivariate logistic regression analyses were used to reveal the independent risk factors of SSI. A bacterial distribution histogram and drug-sensitive heat map were drawn to describe the pathogenic characteristics. RESULTS: Included 3978 patients 138 of them developed SSI with an incidence rate of 3.47% postoperatively. By logistic regression analysis, we found that variables such as gender (males) (odds ratio (OR) = 2.012, 95% confidence interval (CI): 1.235 - 3.278, p = 0.005), diabetes mellitus (OR = 5.848, 95% CI: 3.513 - 9.736, p < 0.001), hypoproteinemia (OR = 3.400, 95% CI: 1.280 - 9.031, p = 0.014), underlying disease (OR = 5.398, 95% CI: 2.343 - 12.438, p < 0.001), hormonotherapy (OR = 11.718, 95% CI: 6.269 - 21.903, p < 0.001), open fracture (OR = 29.377, 95% CI: 9.944 - 86.784, p < 0.001), and intraoperative transfusion (OR = 2.664, 95% CI: 1.572 - 4.515, p < 0.001) were independent risk factors for SSI, while, aged over 59 years (OR = 0.132, 95% CI: 0.059 - 0.296, p < 0.001), prophylactic antibiotics use (OR = 0.082, 95% CI: 0.042 - 0.164, p < 0.001) and vacuum sealing drainage use (OR = 0.036, 95% CI: 0.010 - 0.129, p < 0.001) were protective factors. Pathogens results showed that 301 strains of 38 species of bacteria were harvested, among which 178 (59.1%) strains were Gram-positive bacteria, and 123 (40.9%) strains were Gram-negative bacteria. Staphylococcus aureus (108, 60.7%) and Enterobacter cloacae (38, 30.9%) accounted for the largest proportion. The susceptibility of Gram-positive bacteria to Vancomycin and Linezolid was almost 100%. The susceptibility of Gram-negative bacteria to Imipenem, Amikacin, and Meropenem exceeded 73%. CONCLUSION Orthopedic surgeons need to develop appropriate surgical plans based on the risk factors and protective factors associated with postoperative SSI to reduce its occurrence. Meanwhile, it is recommended to strengthen blood glucose control in the early stage of admission and for surgeons to be cautious and scientific when choosing antibiotic therapy in clinical practice.
Humans ; Surgical Wound Infection/epidemiology* ; Male ; Female ; Risk Factors ; Retrospective Studies ; Middle Aged ; Adult ; Case-Control Studies ; Fractures, Bone/surgery* ; Aged ; Drug Resistance, Bacterial ; Logistic Models ; Anti-Bacterial Agents/therapeutic use* ; Incidence ; Bacteria/drug effects*

[This corrects the article DOI: 10.1016/j.apsb.2022.05.019.].

Infectious bone defects refer to bone defects accompanied by infection or those that occur during the treatment of bone infection and require surgical intervention. Due to the prolonged course of the disease and the destruction of the osteogenic microenvironment, the treatment is extremely difficult, and two major problems need to be solved: infection control and bone defect repair. In recent years, breakthrough progress has been made in this field. In mechanism research, the pathways by which pathogenic bacteria activate inflammatory responses to disrupt bone repair and the drug-resistance mechanism of methicillin-resistant Staphylococcus aureus (MRSA) have been clarified, providing molecular targets for targeted intervention. In terms of technology, interdisciplinary breakthroughs, such as the combination of targeted release of antibacterial drugs with microcarrier-controlled release systems, low-temperature additive manufacturing, and percutaneous sealing technology for external fixators, have solved key clinical problems. In material development, functional materials like cobalt-titanium-based implants and composite systems integrating antibiotics with bone growth factors have achieved synergy between anti-infection and bone repair. Clinical translation has yielded systematic solutions, and multicenter trials have confirmed that their efficacy is superior to traditional methods, breaking the dilemma that anti-infection and bone repair cannot be achieved simultaneously. For bone defect repair, bone repair materials include autologous bone, allogeneic bone, heterologous bone, and artificial bone. Autologous bone is regarded as the gold standard, and technologies to enhance biological activity have emerged in recent years. The Masquelet technique (membrane-induced technique) involves a two-stage surgery; the induced membrane exerts multiple effects, and its large-scale application in our center has achieved favorable outcomes. The Ilizarov technique is based on the Law of Tension-Stress, which has both advantages and limitations, and has been modified in multiple dimensions to form a mature technical system. However, the treatment of infectious bone defects still faces challenges such as unclear mechanisms of persistent infection and intracellular colonization of bacteria. In the future, interdisciplinary collaboration is required to establish an infection control-microenvironment remodeling-structural reconstruction system, promoting the development of personalized, minimally invasive, and intelligent treatment. Additionally, synergistic breakthroughs in clinical technology and biomaterials are needed to overcome this intractable orthopedic disease.

Objective To investigate the distribution characteristics of treatment time for total marrow irradiation (TMI) or total marrow and lymphoid irradiation (TMLI) based on helical tomotherapy, establish a time parameter framework for the application of TMI/TMLI techniques, and provide a basis for optimizing clinical treatment efficiency, predicting patient tolerance, and streamlining workflow. Methods A retrospective analysis was conducted on 57 patients who received TMI/TMLI using helical tomotherapy between November 2024 and July 2025. Patients were stratified by height ( ≤ 130 cm group vs. > 130 cm group). Megavoltage computed tomography scanning time, beam-on time, and total treatment time were recorded. The relationship between height and treatment time was analyzed using Spearman correlation analysis. An independent samples t-test was used to compare treatment time between TMI and TMLI modes. Results In the ≤ 130 cm group, the mean megavoltage computed tomography scanning time, beam-on time, and total treatment time per fraction were (9.67 ± 1.47), (39.96 ± 9.08), and (49.63 ± 10.16) minutes, respectively. In the > 130 cm group, the corresponding times were (14.52 ± 1.17), (60.45 ± 11.19), and (74.97 ± 11.82) minutes, respectively. Treatment time was positively correlated with height (r = 0.756, P < 0.001). Among patients taller than 130 cm, there was no statistically significant difference in treatment time between the TMI and TMLI (P > 0.05). Conclusion Although helical tomotherapy requires a relatively long treatment time, its technical characteristics are well-suited for the extensive and complex target volumes involved in TMI/TMLI. Future technological upgrades and standardized stratification hold promise for enhancing both efficiency and precision, thereby expanding clinical applicability.

Objective:To investigate the expressions of cystathionine-β-synthase(CBS)and cystathionine-γ-lyase(CSE)and their effects on the malignant biological behaviours of breast cancer cells,and to elucidate their mechanisms.Methods:The breast cancer tissue and paracancerous normal tissue from 15 cases of patients were selected,and RT-qPCR and Western blotting methods were used to detect the mRNA and protein expression levels of CBS and CSE in breast cancer tissue,paracancerous normal tissue,MCF-7 cells,and MDA-MB-231 cells.The MCF-7 cells were divided into siNC group(transfected with siNC)and siCBS group(transfected with siCBS),and the MDA-MB-231 cells were divided into ovNC group(transfected with CSE over-expression empty plasmid)and ovCSE group(transfected with CSE over-expression plasmid).CCK8 assay was used to detect the proliferation activities of breast cancer cells in various groups,Transwell assay was used to detect the numbers of migration and invasion cells in various groups,and Western blotting method was used to detect the protein expression levels of E-cadherin,N-cadherin and Vimentin proteins in the breast cancer cells in various groups.Results:Compared with paracancerous normal tissue,the expression levels of CBS and CSE mRNA and proteins in breast cancer tissue were increased(P＜0.05 or P＜0.01).Compared with MDA-MB-231 cells,the CBS mRNA expression level in the MCF-7 cells was increased(P＜0.05);compared with MCF-7 cells,the expression level of CSE protein in the MDA-MB-231 cells was decreased(P＜0.05).Compared with siNC group,the proliferation activity,the numbers of migration and invasion cells,the expression levels of N-cadherin and Vimentin proteins in the MCF-7 cells in siCBS group were significantly decreased(P＜0.05),and the expression level of E-cadherin protein was increased(P＜0.05).Compared with ovNC group,the proliferation activity,the numbers of migratoin and invasion cells,and the expression levels of N-cadherin and Vimentin proteins in the MDA-MB-231 cells in ovCSE group were increased(P＜0.05),while the expression level of E-cadherin protein was significantly decreased(P＜0.05).Conclusion:The expressions of CBS and CSE are upregulated in breast cancer tissue,and high levels of CBS and CSE promote proliferation,migration,invasion and epithelial-mesenchymal transition(EMT)of breast cancer cells.

Objective To evaluate the correlation of L4-5 multifidus muscle(MM)fat infiltration(FI)with lumbar range of motion(LROM)and quality of life in patients with degenerative spinal deformity(DSD).Methods Thirty patients with DSD were included.The Cobb angle,lumbar lordosis(LL),thoracic kyphosis(TK)and TK/LL were measured after the full-length spinal tablet was completed.Thirity-five healthy volunteers were included as the control group.The general conditions and history of underlying diseases were collected for both populations.FI of L4-5 MM was obtained by single-voxel MR spectroscopy(SV-MRS).The forward flexion,posterior extension,left/right lateral flexion LROM were measured.The lower back pain was assessed using visual analogue scale(VAS).The quality of life was assessed using Roland-Morris Disability Questionnaire(RDQ).Individual activity intensity was assessed using International Physical Activity Questionnaire(IPAQ).By comparing the difference in LROM,MM FI,RDQ scores between DSD group and control group,the correlation of RDQ scores in DSD group with MM FI,LROM,Cobb angle,LL,TK,and TK/LL were analyzed,respectively.Results The VAS score was higher in DSD group than that in control group(P＜0.05).In terms of consistency,the DSD group had good forward flexion and posterior extension reliability,strong convex lateral flexion reliability and general concave lateral flexion reliability.The control group had good reliability of forward flexion and posterior extension,while the left/right lateral flexion reliability was general.There was no statistically significant difference in IPAQ score between two groups and FI of the left/right MM in the control group(P＞0.05).Bilateral MM FI was negatively correlated with posterior extension in DSD group(r=-0.395),MM FI(convex side)was negatively correlated with VAS(r=-0.381),RDQ scores was negatively correlated with forward flexion and sagittal ROM,respectively(r=-0.441,-0.425),Cobb angle was positively correlated with posterior extension(r=0.372),TK was positively correlated with MM FI on the concave side(r=0.460)and negatively correlated with forward flexion and sagittal ROM(r=-0.406,-0.410),LL was positively correlated with FI on the concave side(r=0.412),TK/LL was negatively correlated with forward flexion,sagittal ROM and lateral flexion(convex side)(r=-0.424,-0.370,-0.576).Stepwise linear regression analysis indicated that the RDQ score=13.070-flexion×0.228+VAS×1.900.Conclusions Patients with DSD showed a decreased LROM,an increased MM FI and a decreased RDQ score.Clinically,the LROM and paravertebral muscle degeneration should be evaluated comprehensively in DSD.

Objective:To analyze the clinical effect of XinjiaHuanglong Decoction add and subtract combined with auricular point sticking on delirium after hip fracture in elderly patients.Methods:Select 80 elderly patients with postoperative delirium after hip fracture admitted to our hospital from January 2022 to June 2024,and divide them into a matched group and an observation group,with 40 cases in each group.The matched group was treated with olanzapine,and the observation group was treated with XinjiaHuanglong Decoction add and subtract combined with auricular point sticking.Inflammatory response indexes(IL-6,TNF-α,hs-CRP)and stress response indexes(dopamine(DA),5-hydroxytryptamine(5-HT)were detected before and Post-treatment in both groups.Compare the Delirium Rating Scale 98(DRS-R-98)scores,Mini Mental State Examination(MMSE)scores,and duration of delirium between two groups before and Post-treatment,comprehensively evaluate the efficacy,and record the occurrence of adverse reactions.Results:Post-treatment,the DRS-R-98 score in the observation group was lower than that in the matched group,and the MMSE score was higher than that in the matched group(P＜0.05);The duration of delirium in the observation group was shorter than that in the matched group,and the overall effective rate was higher than that in the matched group(P＜0.05).The levels of inflammatory response indicators in the observation group were lower than those in the matched group Post-treatment(P＜0.05);The level of stress response indicators in the observation group was lower than that in the matched group Post-treatment(P＜0.05);There was no difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion:XinjiaHuanglong Decoction add and subtract combined with auricular point sticking has a certain effect on improving delirium after hip fracture in the elderly,and can shorten the duration of delirium,which may be related to reducing inflammation and stress response,and it is safe and worthy of clinical application.

For middle-aged and elderly patients with conditions such as spinal fractures and degenerative spinal diseases, spinal internal fixation is a core surgical procedure for reconstructing spinal stability, heavily relying on the biomechanical stability provided by pedicle screw systems. Whereas, these patients are often complicated by osteoporosis that can significantly compromise the stability of the bone-pedicle screw interface, leading to a marked increase in pedicle screw loosening and surgical failure rates. The bone cement-augmented pedicle screw technique, which involves injecting bone cement into the vertebral body or screw trajectory to optimize the mechanical properties of the bone-pedicle screw composite, has been proven to significantly enhance fixation strength and effectively prevent screw-related failures, thereby reducing the incidence of internal fixation failure in high-risk populations undergoing spinal fusion. However, the widespread clinical application of this technique has faced challenges such as inaccurate clinical decision-making (indication and contraindication selection), non-standardized operative practices, and insufficient awareness of complication prevention, resulting in considerable variability in clinical outcomes and even severe complications. To address this, Prof. Luo Fei from First Affiliated Hospital of Army Medical University initiated the project and the Chinese Association Orthopaedic Surgeons organized relevant experts to develop the Evidence-based clinical practice guideline for bone cement-augmented pedicle screw technique ( version 2025), based on current evidence. The guidelines put forward 8 recommendations regarding the clinical value, scope of application, and operational standards of the technique, aiming to provide evidence-based medical support and technical standardization for clinical decision-making.